scholarly journals Serum miR-122 and Human Genomic DNA in Patients With Drug-Induced Acute Liver Failure or With Chronic Hepatitis C

2011 ◽  
Vol 140 (5) ◽  
pp. S-951
Author(s):  
R Kenton Devine ◽  
Hejun Yuan ◽  
Mamta K. Jain ◽  
Corron M. Sanders ◽  
Nahid Attar ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Chronic Hepatitis C ◽  
Genomic Dna ◽  
Drug Induced ◽  
Human Genomic ◽  
Human Genomic Dna

scholarly journals Micro-RNA-122 levels in acute liver failure and chronic hepatitis C

2014 ◽  
Vol 86 (9) ◽  
pp. 1507-1514 ◽  
Author(s):  
Perry H. Dubin ◽  
Hejun Yuan ◽  
Robert K. Devine ◽  
Linda S. Hynan ◽  
Mamta K. Jain ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Chronic Hepatitis C ◽  
Micro Rna

scholarly journals Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Shih Yea Sylvia Wu ◽  
Bridget Faire ◽  
Edward Gane
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Kidney Injury ◽  
Complete Recovery ◽  
Final Diagnosis ◽  
Community Acquired Pneumonia ◽  
Drug Induced ◽  
First Case ◽  
Life Threatening

VIEKIRA PAK (ritonavir-boosted paritaprevir/ombitasvir and dasabuvir) is an approved treatment for compensated patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. This oral regimen has minimal adverse effects and is well tolerated. Cure rates are 97% in patients infected with HCV GT 1a and 99% in those with HCV GT 1b. We report the first case of life-threatening allergic pneumonitis associated with VIEKIRA PAK. This unexpected serious adverse event occurred in a 68-year-old Chinese female with genotype 1b chronic hepatitis C and Child-Pugh A cirrhosis. One week into treatment with VIEKIRA PAK without ribavirin, she was admitted to hospital with respiratory distress and acute kidney injury requiring intensive care input. She was initially diagnosed with community acquired pneumonia and improved promptly with intravenous antibiotics and supported care. No bacterial or viral pathogens were cultured. Following complete recovery, she recommenced VIEKIRA PAK but represented 5 days later with more rapidly progressive respiratory failure, requiring intubation and ventilation, inotropic support, and haemodialysis. The final diagnosis was drug induced pneumonitis.

scholarly journals Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir

2015 ◽  
Vol 45 (10) ◽  
pp. E156-E160 ◽  
Author(s):  
Akira Okajima ◽  
Kanji Yamaguchi ◽  
Hiroyoshi Taketani ◽  
Tasuku Hara ◽  
Hiroshi Ishiba ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Injury ◽  
Chronic Hepatitis C ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Omar Y. S. Mousa ◽  
Rossa Khalaf ◽  
Rhonda L. Shannon ◽  
Chukwuma I. Egwim ◽  
Scott A. Zela ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Maculopapular Rash ◽  
Virus Genotype ◽  
Drug Induced ◽  
Gradual Improvement ◽  
Complication Risk ◽  
Systemic Symptoms ◽  
High Index Of Suspicion

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare yet severe adverse drug-induced reaction with up to 10% mortality rate. Recent clinical trials reported an association between DRESS and telaprevir (TVR), an NS3/4A protease inhibitor of chronic hepatitis C (CHC) virus genotype 1. Its diagnosis is challenging given the variable pattern of cutaneous eruption and the myriad internal organ involvement. We present two patients who are middle-aged, obese, and white with CHC cirrhosis. They both developed a progressive diffuse, painful pruritic maculopapular rash at weeks 8 and 10 of CHC therapy with TVR, Peg-Interferon alfa-2a, and Ribavirin. They had no exposures to other medications that can cause this syndrome. Physical exam and labs and skin biopsy supported a “Definite” clinical diagnosis of DRESS, per RegiSCAR criteria. Thus Telaprevir-based triple therapy was discontinued and both patients experienced rapid resolution of the systemic symptoms with gradual improvement of eosinophilia and the skin eruption. These two cases illustrate the paramount importance of having a high index of suspicion for TVR-induced DRESS, critical for early diagnosis. Immediate discontinuation of TVR is essential in prevention of a potentially life-threatening complication. Risk factors for development of DRESS in patients receiving TVR remain to be elucidated.

Cut-off level of serum cytokeratin 18 for diagnosis of acute-on-chronic liver failure in chronic hepatitis C cirrhosis

2020 ◽  
Vol 73 ◽  
pp. S226
Author(s):  
Hany Shabana ◽  
Sayed abd Elmaqsood ◽  
Mohamed El-Saadany ◽  
Shymaa Aleraky ◽  
Mohammed Al Arman
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Failure ◽  
Chronic Hepatitis C ◽  
Chronic Liver ◽  
Chronic Liver Failure ◽  
Cytokeratin 18

Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C

2019 ◽  
Author(s):  
Diana Ivanova ◽  
Sergey Borisov ◽  
Dmitriy Kudlay ◽  
Nicolay Nikolenko ◽  
Ludmila Slogotskaya ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Injury ◽  
Pulmonary Tuberculosis ◽  
Chronic Hepatitis C ◽  
Drug Induced ◽  
Drug Induced Liver Injury
Sign in / Sign up

Export Citation Format

Share Document